What is XLO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for XLO?

P/E (TTM) is n/a and 52-week range is $6.47 to $12.58 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s XLO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for XLO?

The company profile lists revenue (TTM) near $20M, net income (TTM) near $-673M, EPS (TTM) near $-1.54 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Xilio Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 6M shares outstanding, ISIN US98422T2096 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Xilio Therapeutics Inc

$XLO

Health Care · Biotechnology

IR Run Scenarios

$9.05

+0.44%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Its pipeline products include Vilastobart, Efarindodekin alfa, XTX501, and masked T cell engagers. Vilastobart is an investigational masked, Fc-enhanced anti-CTLA-4 designed to block CTLA-4 and deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). XTX501 is a novel bispecific PD-1 / masked IL-2 designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function. Its masked T cell engager programs consist of PSMA and STEAP1 with co-stimulation and CLDN18.2. The masked T cell engagers include molecules with one or more tumor-associated antigen (TAA) binding domains and a CD3 targeting domain.

Employees

Website

xiliotx.com/

IPO

2021-10-22

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)